MYCN and neoplasm: To assess the prognosis of individual patients, the International Neuroblastoma Risk Group (INRG) has developed a pre-treatment risk scheme built on clinical, pathological, and genetic factors like age, histologic category, grade of tumor differentiation, MYCN oncogene and chromosome 11q copy number variations (CNVs), and DNA ploidy [9, 10].